Search Results - "Bengoudifa, Bourras-Rezki" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

by Richardson, Paul G., Hungria, Vânia T.M., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios Athanasios, Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Binlich, Florence, San-Miguel, Jesús F.
Published in Blood (11.02.2016)

Get full text

Journal Article

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

by San-Miguel, Jesús F, Hungria, Vania T M, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A, Elghandour, Ashraf, Jedrzejczak, Wieslaw W, Günther, Andreas, Nakorn, Thanyaphong N, Siritanaratkul, Noppadol, Schlossman, Robert L, Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae H, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Binlich, Florence, Richardson, Paul G
Published in The Lancet. Haematology (01.11.2016)

Get more information

Journal Article

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

by Sierra, Jorge, Montesinos, Pau, Thomas, Xavier, Griskevicius, Laimonas, Cluzeau, Thomas, Caillot, Denis, Legrand, Ollivier, Minotti, Clara, Luppi, Mario, Farkas, Firas, Bengoudifa, Bourras-Rezki, Gilotti, Geralyn, Hodzic, Sejla, Rambaldi, Alessandro, Venditti, Adriano
Published in Blood advances (14.11.2023)

Get full text

Journal Article

$Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial$

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

by San-Miguel, Jesús F, Prof, Hungria, Vânia T M, MD, Yoon, Sung-Soo, Prof, Beksac, Meral, Prof, Dimopoulos, Meletios Athanasios, Prof, Elghandour, Ashraf, Prof, Jedrzejczak, Wieslaw Wiktor, Prof, Günther, Andreas, MD, Nakorn, Thanyaphong Na, MD, Siritanaratkul, Noppadol, MD, Corradini, Paolo, Prof, Chuncharunee, Suporn, MD, Lee, Je-Jung, Prof, Schlossman, Robert L, MD, Shelekhova, Tatiana, PhD, Yong, Kwee, Prof, Tan, Daryl, MRCP, Numbenjapon, Tontanai, MD, Cavenagh, Jamie D, MD, Hou, Jian, Prof, LeBlanc, Richard, MD, Nahi, Hareth, Prof, Qiu, Lugui, Prof, Salwender, Hans, MD, Pulini, Stefano, MD, Moreau, Philippe, Prof, Warzocha, Krzysztof, Prof, White, Darrell, Prof, Bladé, Joan, MD, Chen, WenMing, Prof, de la Rubia, Javier, Prof, Gimsing, Peter, MD, Lonial, Sagar, Prof, Kaufman, Jonathan L, MD, Ocio, Enrique M, MD, Veskovski, Ljupco, MD, Sohn, Sang Kyun, Prof, Wang, Ming-Chung, MD, Lee, Jae Hoon, Prof, Einsele, Hermann, Prof, Sopala, Monika, PhD, Corrado, Claudia, MD, Bengoudifa, Bourras-Rezki, MS, Binlich, Florence, MD, Richardson, Paul G, Prof
Published in The lancet oncology (01.10.2014)

Get full text

Journal Article

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

by Bengoudifa, Bourras-Rezki, Weber, Hans, Gathmann, Insa, Hoenekopp, Albert, Berkowitz, Noah
Published in Blood (29.11.2018)

Get full text

Journal Article

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

by Kiladjian, Jean-Jacques, Harrison, Claire, Mesa, Ruben A., Al-Ali, Haifa K., Mascarenhas, John, Sanabria, Fabian, Bürki, Julie Vienne, Bengoudifa, Bourras-Rezki, Passamonti, Francesco
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)

Get full text

Journal Article

POSTER: MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

POSTER: MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

by Kiladjian, Jean-Jacques, Harrison, Claire, Mesa, Ruben A., Al-Ali, Haifa K., Mascarenhas, John, Sanabria, Fabian, Bürki, Julie Vienne, Bengoudifa, Bourras-Rezki, Passamonti, Francesco
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)

Get full text

Journal Article

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

by Sierra, Jorge, Montesinos, Pau, Thomas, Xavier, Griškevičius, Laimonas, Cluzeau, Thomas, Caillot, Denis, Legrand, Ollivier, Minotti, Clara, Luppi, Mario, Farkas, Firas, Bengoudifa, Bourras-Rezki, Gilotti, Geralyn, Hodzic, Sejla, Rambaldi, Alessandro, Venditti, Adriano
Published in Blood (05.11.2020)

Get full text

Journal Article

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

by Cloos, Jacqueline J, Montesinos, Pau, Fiedler, Walter, Müller, Rouven, Krauter, Jürgen, Sica, Simona, Westermann, Jörg, Heidinga, Maaike E, Ngai, Lok Lam, Oussoren-Brockhoff, Yvonne J.M, Döhner, Hartmut, Levis, Mark, Ossenkoppele, Gert J., Stone, Richard M., Koenen, Giedre, Bengoudifa, Bourras-Rezki, Cheng, Yuan, Medts, Thierry, Heidinger, Valerie, Sachs, Carolin, Sierra, Jorge
Published in Blood (23.11.2021)

Get full text

Journal Article

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

by Zeidan, Amer M., Al-Kali, Aref, Borate, Uma, Cluzeau, Thomas, DeZern, Amy E., Esteve, Jordi, Giagounidis, Aristoteles, Kobata, Krissy, Lyons, Roger, Platzbecker, Uwe, Sallman, David A., Santini, Valeria, Sanz, Guillermo, Sekeres, Mikkael A., Wei, Andrew H., Xiao, Zhijian, Van Hoef, Marlies, Nourry-Boulot, Claire, Sadek, Islam, Bengoudifa, Bourras-Rezki, Sachs, Carolin, Sabo, John, Garcia-Manero, Guillermo
Published in Blood (23.11.2021)

Get full text

Journal Article

Trial in Progress: A Phase 3, Randomized, Double-Blind Study of Midostaurin in Combination with Chemotherapy and as Single-Agent Maintenance Therapy in Newly Diagnosed Patients with FLT3 Mutation–Negative Acute Myeloid Leukemia (AML)

Trial in Progress: A Phase 3, Randomized, Double-Blind Study of Midostaurin in Combination with Chemotherapy and as Single-Agent Maintenance Therapy in Newly Diagnosed Patients with FLT3 Mutation–Negative Acute Myeloid Leukemia (AML)

by Döhner, Hartmut, Sierra, Jorge, Stone, Richard, Hoenekopp, Albert, Berkowitz, Noah, Sachs, Carolin, Bengoudifa, Bourras-Rezki, Ossenkoppele, Gert
Published in Clinical lymphoma, myeloma and leukemia (01.09.2018)

Get full text

Journal Article

$Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma$

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

by San-Miguel, Jesús F., Hungria, Vania T.M., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Richardson, Paul G.
Published in Blood (03.12.2015)

Get full text

Journal Article

$Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment$

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

by San Miguel, Jesús F, Hungria, Vânia TM, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Binlich, Florence, Richardson, Paul G.
Published in Blood (03.12.2015)

Get full text

Journal Article

$Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study$

Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study

by Hungria, Vania T.M., San Miguel, Jesus F., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Na Nakorn, Thanyaphong, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Richardson, Paul G.
Published in Journal of clinical oncology (20.05.2015)

Get full text

Journal Article

$Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1$

Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1

by San Miguel, Jesus F., Hungria, Vania T.M., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Na Nakorn, Thanyaphong, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Richardson, Paul G.
Published in Journal of clinical oncology (20.05.2015)

Get full text

Journal Article

$Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma$

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma

by Richardson, Paul G., Hungria, Vania T.M., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Na Nakorn, Thanyaphong, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, San-Miguel, Jesùs F.
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

$A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)$

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

by Krauter, Jürgen, Schlenk, Richard F., Schaich, Markus, Bouscary, Didier, Dombret, Hervé, Winiger, Ivo J., Squier, Margaret, Bengoudifa, Bourras-Rezki, Ottmann, Oliver G.
Published in Blood (19.11.2010)

Get full text

Journal Article